News Detail

Cellectar BioSciences prices private placement of shares and warrants at up to $140 million

PUBT · 3h ago

Listen to the news

Cellectar BioSciences prices private placement of shares and warrants at up to $140 million

Cellectar BioSciences entered securities purchase agreements for financing of up to USD 140 million, including a concurrent private placement in an unregistered sale.
Private placement covers 2,116,887 common shares, pre-funded warrants for 9,471,086 shares, and 13,206,026 each of milestone-based Tranche A, Tranche B, Tranche C warrants; milestone warrants carry USD 2.65 exercise price.
Company expects USD 35 million upfront, with up to USD 105 million tied to milestone-based securities; proceeds earmarked for confirmatory study, NDA filing plans for iopofosine I 131 in Waldenström macroglobulinemia.
Management also agreed to buy common stock at USD 2.88 per share with accompanying milestone-based warrants at USD 2.88 exercise price.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605050700PRIMZONEFULLFEED9713132) on May 05, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.

What's Trending

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.